MGX.US Metagenomi, Inc. Common Stock

Healthcare Biotechnology USA Stocks
0.6917 USD
Close of Nov 15, 2026
0.6000 1.87
Market cap
USD 26.2M
P/E
-
P/B
0.28x
ROE
-101.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.

Is MGX.US undervalued?

Graham number

The Graham number of Metagenomi, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Metagenomi, Inc. Common Stock fundamental analysis

No fundamental analysis for Metagenomi, Inc. Common Stock yet.

Metagenomi, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Metagenomi, Inc. Common Stock

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin am…

Full company profile